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in patients with cartilage-hair
hypoplasiaTo the Editor:
Cartilage-hair hypoplasia (CHH, MIM #250250) is a metaphy-
seal chondrodysplasia with variable immunodeficiency and
increased risk of malignancy. We previously showed that in pa-
tients with CHH with chronic respiratory symptoms, the preva-
lence of bronchiectasis (BE) is 52%.1 The prevalence of BE
and the contributing risk factors in the overall CHH population
remain unknown. High-resolution computed tomography
(HRCT) is the criterion standard investigation for assessing BE;
however, radiation exposure is a concern. Pulmonary changes in
patients with CHH have not been examined systematically and
the applicability of lungmagnetic resonance imaging (MRI) in as-
sessing their lung pathology is unclear.
We investigated the prevalence of BE in a random cohort of 34
Finnish patients with genetically confirmed CHH (6 men, 28
women; median age, 39 years, range, 13-68 years). All patients or
caregivers gave their written informed consent. The Institutional
Research Ethics Committee approved the study. We collected
clinical data, obtained blood tests, and performed lung HRCT (34
of 34) and MRI (16 of 34) (for detailed imaging protocols, see
Appendix E1 in this article’s Online Repository at www.
jacionline.org). We analyzed the clinical and immunologic corre-
lates with BE with the Fisher exact test, the Mann-Whitney test,
and multiple logistic regression analysis. Performance of MRI
compared with HRCTwas determined by the Spearman rank cor-
relation coefficient (rho).
Table I presents the patients’ clinical and laboratory character-
istics. HRCT showed BE in 10 of 34 patients (29%), aged 29 to
68 years. BE was unilateral (n 5 2) or bilateral (n 5 8) and
was located most commonly in the lower lobes and right middle
lobe, but was also found in all other lobes (Fig 1). Additional find-
ings on HRCT were acute inflammation (n 5 3), fibrosis-like
changes (n 5 6), and nonspecific subpleural nodules of less
than 0.5 cm in size (n 5 8). MRI showed lung abnormalities in
8 of 16 patients and had a good correlation with HRCT (overall
r, 0.820; P < .001) (see Table E1 in this article’s Online Reposi-
tory at www.jacionline.org).
Patients with BE had significantly higher serum IgG and
white blood cells, total lymphocyte, and CD16/561 cell counts
(Table I). However, these parameters correlated significantly
with age (see Fig E1 in this article’s Online Repository at
www.jacionline.org). Patients with BE tended to have more si-
nus infections, pneumonia, and chronic cough (defined as
ongoing daily cough lasting >_1 year). BE was diagnosed in 4
of 6 patients with a history of smoking, but when controlled
for age, this association became insignificant. In the multiple
logistic regression analysis, only higher CD16/561 cell counts
remained associated with the presence of BE (P 5 .026; Bcoefficient, 8.8). Humoral immune defect (defined as IgA defi-
ciency or low IgM levels or low levels of at least 2 IgG sub-
classes or ongoing intravenous immunoglobulin substitution)
was insignificantly more common in patients with BE (5 of
10 vs 11 of 24). Preexisting antibodies to tetanus toxoid were
below the protective level in 2 of 27 patients, both aged 68 years,
one with BE and another without. Serologic responses to poly-
saccharide pneumococcal vaccine (measured in 5 patients) were
abnormal in subjects with and without BE. Retrospective data
on lymphocyte mitogen stimulation showed decreased re-
sponses in 6 of 8 patients, all without BE. Noteworthily, 2 pa-
tients with BE had normal laboratory parameters, except for
low CD271IgD1 B cells.
BE is a known complication of combined variable immunode-
ficiency and detected in more than 20% of patients,7 correspond-
ing to the prevalence of 29% in our study cohort. However, our
findings suggest that BE often develops also in CHH patients
with inapparent immunodeficiency, implicating the presence of
other contributing factors. Hyaline cartilage, in contrast to growth
plate cartilage, is not affected in CHH and thus tracheal and bron-
chial defects are unlikely to play a role. Although the underlying
cause of BE cannot be detected on the basis of lobar involvement,
the distribution of BE in our cohort was similar to the pattern in
patients with bronchiolitis obliterans.8 This echoes our finding
of fibrosis-like changes in 18% of patients with CHH and requires
further studies. Most of our patients reported absent or mild
respiratory symptoms and had never been evaluated by lung
HRCT. However, half of those with BE reported chronic cough,
emphasizing the need for regular follow-up even in mildly symp-
tomatic individuals. Also, in individuals with short stature and BE
of unknown etiology, the diagnosis of CHH should be considered.
In patients with immunodeficiency, lung disease such as BE or
parenchymal changes contribute to poorer prognosis.6 Out of 8
previously reported patients with BE, 1 died from pneumonia at
58 years; others had significant respiratory symptoms and 6 suf-
fered from pneumonia.1 BE was progressive in all those with lon-
gitudinal follow-up extending to adulthood.1 Another report
described a young adult with CHH, frequent infectious exacerba-
tions and rapid progression of BE, leading to fatal septicemic
pneumonia within 2 years.9
We previously reported higher IgG levels in infection-prone
patients with CHH.2 Here, we find the same trend, as well as
higher white blood cells, total lymphocyte, and CD16/561 cell
counts in CHH patients with BE. These findings may be
explained by exacerbated inflammatory responses in the respira-
tory tract, smoking, chronic smoldering infections, impaired
specific antibody production, or BE-induced systemic immune
response.10
Patients in our cohort more often had low CD191 (67% [22 of
33]) than low CD31 (33% [11 of 33]) cell counts. Total IgG con-
centrations were normal in all, including levels in patients before
initiation of IVIG therapy. However, almost half the patients
(47%) had humoral immune defects and 4 of 5 tested patients
showed specific antibody deficiency, suggesting that immuno-
globulin substitution may be beneficial despite normal IgG levels.
We excluded 3 patients receiving IVIG at the time of the study
from IgG and subclass analysis. However, when we included
IgG levels available for 2 of these patients before initiation of
IVIG therapy, the difference between median IgG levels in pa-
tients with and without BE became even more significant
(P 5 .009).
TABLE I. Comparison of clinical and laboratory characteristics of patients with and without BE
Characteristics
Normal values
for adults* Patients with BE
Patients
without BE P value
Median age (y) (range) 59.5 (29-68) 36.5 (13-68) .023
Sex F 70% (7 of 10)
M 30% (3 of 10)
F 88% (21 of 24)
M 12% (3 of 24)
.328
History of chronic cough 50% (5 of 10) 17% (4 of 24) .085
History of sinusitis 90% (9 of 10) 63% (15 of 24) .215
History of otitis media 70% (7 of 10) 75% (18 of 24) 1
History of pneumonia 30% (3 of 10) 21% (5 of 24) .666
History of physician-diagnosed asthma 30% (3 of 10) 29% (7 of 24) 1
History of allergic rhinitis 60% (6 of 10) 38% (9 of 24) .276
History of smoking 40% (4 of 10) 8% (2 of 24) .048
Previous or ongoing IVIG substitution 0% (0 of 10) 17% (4 of 24) .296
IgG (g/L) 6.8-15.0 13.0 (10.1-15.7) 10.6 (6.2-15.9) .013
IgG2 (g/L) 1.50-6.40 2.03 (0.27-4.01) 2.00 (0.55-4.52) .755
IgG3 (g/L) 0.20-1.10 0.43 (0.17-1.17) 0.45 (0.12-1.20) .724
IgG4 (g/L) 0.08-1.40 0.09 (0.00-0.82) 0.08 (0.00-0.47) .724
IgA (g/L) M 0.88-4.84
F 0.52-4.02
2.82 (1.24-4.95) 1.83 (0.00-7.49) .086
IgM (g/L) M 0.36-2.59
F 0.47-2.84
0.89 (0.28-2.47) 0.99 (0.20-3.06) .512
IgE (kU/L) 0-100 34 (10-98) 13 (2-254) .205
WBC (3109 cells/L) 3.4-8.2 6.8 (4.7-12.0) 4.8 (1.2-11.1) .034
Neutrophil count (3109 cells/L) 1.5-6.7 4.26 (2.22-8.40) 3.31 (0.28-7.88) .137
Total lymphocyte count (3109 cells/L) 1.3-3.6 1.76 (1.16-3.25) 1.21 (0.26-2.22) .008
CD31 cell count (3109 cells/L) 0.85-2.28 1.24 (0.57-3.01) 0.90 (0.16-1.91) .051
CD41 cell count (3109 cells/L) 0.458-1.406 0.711 (0.353-1.287) 0.524 (0.118-1.312) .123
CD81 cell count (3109 cells/L) 0.24-0.98 0.52 (0.15-1.72) 0.30 (0.04-0.76) .068
CD3/CD4/CD45RA/CD311 cell count (3109 cells/L) 0.05-2.4 0.011 (0.003-0.171) 0.030 (0.000-0.247) .269
CD16/561 cell count (3109 cells/L) 0.08-0.57 0.25 (0.11-0.55) 0.14 (0.07-0.36) .008
CD191 cell count (3109 cells/L) 0.12-0.43 0.11 (0.04-0.22) 0.11 (0.00-0.28) .524
CD271 IgD1 B-cell count (cells/mL) 9-88 5,9 (2.9-13.3) 6.5 (0.0-20.9) .603
CD271 IgD2 B-cell count (cells/mL) 13-122 12.8 (3.9-59.6) 10.6 (0.0-63.8) .269
Antibodies to tetanus toxoid (IU/mL) >0.1 2.85 (0.07-4.60) 2.35 (0.05-8.90) .621
Good response to immunization with PPV (no. of serotypes)§ 7 4 (3-5) 6 (1-7) .773
Values for laboratory parameters are presented as median (range). P values less than .05 were considered significant and are in boldface.
BE, Bronchiectasis; F, female; IVIG, intravenous immunoglobulin; M, male; PPV, polysaccharide pneumococcal vaccine (Pneumovax); WBC, white blood cell.
*Local laboratory or previously published reference values2-6 were applied for the tested parameters.
Spearman correlation coefficient (rho) 0.392 (P 5 .022).
One patient with BE and 3 patients without BE had a history of recurrent pneumonia.
§Good response was defined as a 4-fold rise in serotype-specific antibodies measured with fluoroimmunoassay and a postimmunization antibody level of >_0.35 mg/mL.
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in our cohort than in the general population of Finnish adults
(24% vs 6% and 44% vs 15% to 25%, respectively).11,12 These
conditions may have been misdiagnosed as the cause of respira-
tory symptoms in some of the patients, or individuals with
CHH suffer from immune dysregulation. Serum total IgE level
was normal in 31 patients and increased in 1 subject (Table I)
who had no allergic symptoms, but reported repeated sinusitis
in adulthood. Asthma diagnostics in CHH is complicated by dif-
ficulties in interpreting spirometry due to short stature and
absence of disease-specific reference values. Asthma diagnosis
should not replace lung imaging in CHH patients with chronic
respiratory symptoms.
Lung HRCT remains the criterion standard for diagnosing
BE, but we found a good correlation between HRCT and MRI
scores when assessing BE in patients with CHH. Lung MRI
may potentially thus replace HRCT in follow-up, sparing
these malignancy-prone patients from repeated radiation
exposure.
We recognize some limitations in our study. We recruited
patients regardless of their clinical presentation and this may haveled to selection bias. However, most participants had no current
respiratory complaints. Patients deceased from infections or
aggressive lymphoma may constitute a more severely affected
group that was absent from our cohort. However, 2 of our patients
had survived lymphoma, and 4 were on immunoglobulin therapy,
representing more severely immunocompromised subjects. We
did not systematically screen for other potential causes of BE, but
our patients with BE (youngest 29 years) lacked typical
symptoms of cystic fibrosis or primary ciliary dyskinesia, both
of which have low prevalence in Finland. Lymphocyte prolifer-
ative responses to mitogens were not systematically evaluated
because we13 and others14 have previously shown that responses
are abnormal in most of the patients and correlate poorly with
clinical parameters in CHH. Of the patients with BE, 6 of 10
were older than 58 years, and the prevalence of BE in this age
group in healthy individuals is around 15%.15 However, the prev-
alence in this age group was significantly higher (55%, 6 of 11) in
our cohort. We diagnosed BE in a patient as young as 29 years,
underscoring the necessity of early BE screening.
Because BE can lead to recurrent lung infections and even
death in patients with CHH, lung pathology should be actively
FIG 1. Lung abnormalities on MRI and HRCT images of a 35-year-old male patient with CHH. A male patient
aged 35 years with bronchiectasis (white arrows) and mucous plugging (white asterisks) in the left lower
lobe on axial HRCT slice (A) and MRI (B, Axial gadolinium-enhanced T1-weighted gradient-echo sequence;
C, coronal breath-hold Single Shot Turbo Spin Echo). With gadolinium-enhanced dynamic perfusion T1-
weighted sequence (D), hypoperfusion of the left lower lobe (black asterisk) was observed.
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diagnosis of BE influences ongoingmanagement and treatment of
possible future respiratory infections. Given the applicability and
safety of lungMRI, we recommend scheduled lung imaging in all
adults with CHH. Prospective studies are needed to determine the
rate of BE progression and mortality, and to elucidate the
pathogenetic mechanisms leading to BE development in CHH.
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http://dx.doi.org/10.1016/j.jaci.2016.07.023CorrectionsWith regard to the article in the October 2016 issue entitled ‘‘Rapid molecular diagnostics of severe primary
immunodeficiency determined by using targeted next-generation sequencing’’ (J Allergy Clin Immunol 2016;138:1142-
51.e2), the authors wish to note 2 incorrect terms. In Table II (page 1145), one of the JAK3 pathogenic variants for the S2
sample should be corrected as ‘‘c.2297_2298delAGinsC (p.Q766Pfs*79),’’ rather than ‘‘c.2297_2298delAGinsC
(p.R767Efs*10).’’ Additionally, in the first paragraph of the last results section ‘‘Leaky SCID and combined variable
Immunodeficiencies’’ (page 1146) and Table IV (page 1149), the homozygous RAG1 variant of Patient 15 (P15) should
be corrected as ‘‘c.1541T>G (p.L514R),’’ rather than ‘‘c.1514T>G (p.L514R). The authors regret these errors.With regard to the article in the October 2016 issue entitled ‘‘Pharmacogenomics and adverse drug reactions: Primetime
and not ready for primetime tests’’ (JAllergy Clin Immunol 2016;138:943-55), it has been brought to the Editors’ attention
that an incorrect gene was used in the upper paragraphs in the second column on page 951. The term HLA-B*1502 is used
instead of HLA-B*5801. The authors regret the error.
